Celiac crisis in a patient with chronic lymphocytic leukemia and hypogammaglobulinemia.

11:41 EDT 19th April 2015 | BioPortfolio

Summary of "Celiac crisis in a patient with chronic lymphocytic leukemia and hypogammaglobulinemia."

Celiac crisis is an acute, fulminant form of celiac disease manifesting with severe diarrhea, metabolic and electrolyte abnormalities, and weight loss. It is mostly seen in children, and there are very few reports in adults. We present a 67-year-old patient with chronic lymphocytic leukemia (CLL) who presented with weight loss of 40pounds, severe diarrhea, hypoalbuminemia and hypokalemia. The patient was immunosuppressed with hypogammaglobulinemia, which is common in CLL. Thus, the patient had negative serological studies for celiac disease. An endoscopic evaluation and HLA typing supported the diagnosis of celiac disease. Although the differential diagnosis was broad, exclusion of other etiologies for diarrhea, prompt diagnosis of celiac disease and initiation of gluten-free diet resolved the crisis. This is the first such report of a patient presenting with celiac crisis on a background of hypogammaglobulinemia.

Affiliation

Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, 72205 Arkansas, USA.

Journal Details

This article was published in the following journal.

Name: Gastroenterologie clinique et biologique
ISSN: 2210-7401
Pages:

Links

PubMed Articles [16771 Associated PubMed Articles listed on BioPortfolio]

Coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasm.

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. Host immune surveillance caused mainly by the disease itself is speculated to be responsible for high inciden...

SnapShot: Chronic Lymphocytic Leukemia.

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in western countries. This SnapShot depicts the origins and evolution of this B cell malignancy, describes prognostic factor...

Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.

Inactivation of the Ataxia Telangiectasia Mutated gene in chronic lymphocytic leukemia results in resistance to p53-dependent apoptosis and inferior responses to treatment with DNA damaging agents. He...

The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience.

Chronic lymphocytic leukemia and small lymphocytic lymphoma are 2 different presentations of the most common B-cell neoplasm in western countries (CLL/SLL). In this disease, kidney involvement is usua...

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Lenalidomide is an immunomodulatory agent clinically active in chronic lymphocytic leukemia patients. The specific mechanism of action is still undefined, but includes the modulation of microenvironme...

Clinical Trials [5212 Associated Clinical Trials listed on BioPortfolio]

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The primary purpose of this study is to evaluate the safety, toxicities, dosage and response rate for an investigational drug, motexafin gadolinium, administered to patients with chronic l...

Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The primary purpose of this study is to determine if motexafin gadolinium may be an effective treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (...

Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water

Chronic lymphocytic leukemia. B-cell chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the Western Hemisphere, accounting for ~25% of all leukemia's. It represents a ...

Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation

The purpose of this research study is to collect, freeze and store leukemia cells from the blood or bone marrow of patients that have advanced chronic lymphocytic leukemia (CLL) that is no...

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

The purpose of the study is to evaluate the ability of Rituximab maintenance therapy to prolong progression free survival in patients with chronic lymphocytic leukemia, who responded to a ...

Medical and Biotech [MESH] Definitions

A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.

A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.

An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.

Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Top five promising drugs Phase III (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE III TRIALS February 2014 Drug Disease Company Lu-AE58054 Alzheimer’s disease H. Lundbeck / Otsuka Pharmaceutical Patisiran ...

Advertisement